This booklet discusses Darzalex® and Darzalex Faspro®, two formulations of an equally effective medication. This targeted therapy enlists the human immune system to help attack and kill myeloma cells, making it easier for healthy cells to recover after treatment. Darzalex is an FDA-approved standard-of-care (SOC) therapy for newly diagnosed myeloma, and it is also used at all stages of the disease. SOC is a benchmark treatment that is widely accepted by medical experts as the most appropriate.